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Background: Steroids are lipophilic compounds with a gonane skeleton and play an important role in higher
organisms. Due to different functionalizations - mainly hydroxylations - at the steroid molecule, they vary highly in their
mode of action. The pharmaceutical industry is, therefore, interested in hydroxysteroids as therapeutic agents. The
insertion of hydroxyl groups into a steroid core, however, is hardly accomplishable by classical chemical means; that is
because microbial steroid hydroxylations are investigated and applied since decades. CYP106A2 is a cytochrome P450
monooxygenase from Bacillus megaterium ATCC 13368, which was first described in the late 1970s and which is
capable to hydroxylate a variety of 3-oxo-delta4 steroids at position 15beta. CYP106A2 is a soluble protein, easy to
express and to purify in high amounts, which makes this enzyme an interesting target for biotechnological purposes.
Results: In this work a focused steroid library was screened in vitro for new CYP106A2 substrates using a
reconstituted enzyme assay. Five new substrates were identified, including dehydroepiandrosterone and
pregnenolone. NMR-spectroscopy revealed that both steroids are mainly hydroxylated at position 7beta. In
order to establish a biotechnological system for the preparative scale production of 7beta-hydroxylated
dehydroepiandrosterone, whole-cell conversions with growing and resting cells of B. megaterium ATCC1336 the
native host of CYP1062 and also with resting cells of a recombinant B. megaterium MS941 strain overexpressing
CYP106A2 have been conducted and conversion rates of 400 muM/h (115 mg/l/h) were obtained. Using the
B. megaterium MS941 overexpression strain, the selectivity of the reaction was improved from 0.7 to 0.9 for
7beta-OH-DHEA.
Conclusions: In this work we describe CYP106A2 for the first time as a regio-selective hydroxylase for 3-hydroxy-delta5
steroids. DHEA was shown to be converted to 7beta-OH-DHEA which is a highly interesting human metabolite,
supposed to act as neuroprotective, anti-inflammatory and immune-modulatory agent. Optimization of the whole-cell
system using different B. megaterium strains lead to a conversion of DHEA with B. megaterium showing high selectivity
and conversion rates and displaying a volumetric yield of 103 mg/l/h 7beta-OH-DHEA.
Keywords: Cytochrome P450, Steroid hydroxylase, Bacillus megaterium, Whole-cell conversion, Dehydroepiandrosterone,
Microbial, CYP106A2Background
Cytochrome P450 enzymes (P450s) are heme-containing
monooxygenases showing an eponymous absorbance ma-
ximum at 450 nm of the reduced CO-complex [1]. P450s
compose one of the largest and oldest gene families with
representatives in all kingdoms of life [2] were they are
involved in the biosynthesis and tailoring of natural pro-
ducts like sterols, terpenoids, polyketides, alkaloids, and* Correspondence: ritabern@mx.uni-saarland.de
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unless otherwise stated.others [3]. In humans, P450s are, for instance, involved in
the biosynthesis of cholesterol, steroid hormones, vitamin
D, eicosanoids and prostaglandins; furthermore, they are
key enzymes in the biotransformation of xenobiotics in
the liver. Cytochrome P450 enzymes belong to the group
of external monooxygenases, catalyzing the insertion of
one atom of oxygen into a substrate and the concomitant
reduction of the second oxygen atom to water. On
the basis of this mechanism P450s are able to perform a
variety of reactions including N-oxidations, N-, O-, and S-
dealkylations, sulfoxidations, epoxidations, peroxidations,
dehalogenations, N-oxide reductions, and even C–C bondl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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spectrum make cytochrome P450 enzymes interesting
candidates for industrial purposes. The ability of P450 to
introduce hydroxyl groups into non-activated carbon
bonds is unique; this spin-forbidden reaction is only
scarcely feasible in a regioselective manner by classical
chemical means. Hydroxylations are of special interest to
pharmaceutical industry, because the insertion of only one
hydroxyl group into a certain substrate can dramatically
influence its bioavailability, bioactivity or solubility. One
famous example is the P450-dependent formation of pra-
vastatin from compactin. Pravastatin exhibits a consi-
derable increased inhibitory activity against the HMG-
CoA reductase, the key enzyme in cholesterol biosynthesis
[6]. Thus, the assembly of pravastatin using a biocon-
version process developed by Sankyo (present Daiichi-
Sankyo) represents a successful industrial application of
P450s [7]. Another interesting application of P450s is the
production of human metabolites either of endogenous
origin, like hydroxysteroids, or hydroxylated xenobiotics
such as drugs. However, the use of cytochromes P450 is to
date mostly limited to the production of high-value fine
chemicals or pharmaceutically interesting human metabo-
lites for analytical purposes. At the moment, the produc-
tivity of P450 reactions is often not sufficient for the bulk
production of chemicals, due to several limitations like
their multi-component character, their low stability under
process conditions and the consumption of cost-intensive
co-factors (NADPH, NADH) in stoichiometric amounts
[7-9]. Furthermore, human cytochrome P450s are mem-
brane bound proteins, which are difficult to express and
to purify. To overcome at least some of these drawbacks,
whole-cell systems are the method of choice to accom-
plish P450 reactions [8,10].
Steroids are one of the most interesting classes of P450
substrates for pharmaceutical and biotechnological pur-
poses. These terpenoic compounds with a gonane ske-
leton play a vital role in the human metabolism. Steroids
are responsible for the maintenance of blood-pressure and
homeostasis, sex development and stress response. Im-
balances in the steroid level can have severe pathological
effects [11]. Estrogens, for instance, which are produced in
adipose tissue, are involved in the formation of post-
menopausal breast cancer [12]. From a biotechnological
point of view, bacterial steroid hydroxylases have the ad-
vantage, in contrast to their eukaryotic counterparts, that
they are soluble proteins, which facilitates their recombin-
ant expression and purification. CYP106A2 from Bacillus
megaterium ATCC13368 is one of only few cloned bac-
terial steroid hydroxylases which has been investigated
since decades and emerged as a potent biocatalyst for the
preparative scale production of hydroxysteroids [13]. Most
substrates of CYP106A2 are 3-oxo-Δ4 steroids, which are
hydroxylated mainly in the 15β-position [14-16]. So far,conversions of 3-hydroxy-Δ5, ring-reduced or aromatic
steroids with CYP106A2 have not been described. Recent
studies conducted with this enzyme showed, however, that
it is also capable to hydroxylate di- and triterpenoids with
diverse backbones. Bleif et al. identified the diterpene resin
acid abietic acid and the tetracyclic triterpene 11-keto-
β-boswellic acid as substrates of CYP106A2 [17,18].
Screening of a natural product library further broadened
the substrate spectrum of this enzyme, with the identifica-
tion of the less polar triterpenoids dipterocarpol and betu-
line as substrates [19]. Interestingly, the aforementioned
substrates lack a 3-oxo-Δ4 motif and dipterocarpol, betu-
line, and abietic acid do even not contain any keto-en
moiety in their structure, which encouraged us to investi-
gate whether CYP106A2 is yet able to hydroxylate non-3-
oxo-Δ4 steroids. Screening of a focused library consisting
of 11 steroidal compounds, among them 3-hydroxy-Δ5,
A-ring-reduced, aromatic and D-ring-modified steroids
revealed novel non-3-oxo-Δ4 steroid substrates for CYP
106A2, among them dehydroepiandrosterone (DHEA) and
pregnenolone (PREG). NMR analysis showed that both
DHEA and PREG were hydroxylated preferably at position
7β. DHEA was also hydroxylated at position 7α, but to a
minor extend. 7-oxygenated steroids and sterols are wide-
spread in mammals, birds, fish and plants [20]. In humans,
DHEA and PREG are 7α-hydroxylated in various tissues
by different cytochrome P450 enzymes including liver,
intestine, and brain. However, there is no mammalian
enzyme described yet which catalyzes the formation of
7β–OH–DHEA. Experimental and clinical data indicated
that hydroxylated DHEA derivatives are bioactive human
metabolites, responsible for at least some of the DHEA ac-
tions in the body, like neuroprotective, anti-inflammatory
and anti-proliferative effects [21,22]. For these reasons we
established in this work a competitive P450 whole-cell
process for the production of 7β-hydroxylated DHEA.
Results and discussion
Screening of a focused steroid library
Most CYP106A2 substrates contain a 3-oxo-Δ4-moiety
and it was assumed for a long time that this motif is a pre-
requisite for conversions using this enzyme (Table 1).
However, recent findings revealed that CYP106A2 indeed
is able to convert compounds lacking such a motif
[17,18,23], which encouraged us to investigate whether
CYP106A2 is also able to catalyze the hydroxylation of
steroids lacking the 3-oxo-Δ4-moiety. Therefore, a focused
steroid library, consisting of 11 non-3-oxo-Δ4 steroids was
screened in an in vitro enzyme assay. The mitochondrial
electron transfer system from bovine adrenals was used to
reconstitute the CYP106A2 enzyme system, because the
bovine electron transfer proteins are well established as
efficient electron suppliers for CYP106A2 and other bac-
terial P450s [24,25].
Table 1 Steroids tested for conversion with CYP106A2
Steroid Product formation: main
hydroxylation position




























no = no conversion/no spin shift, n.d. = hydroxylation position not determined.
† = tested in this work.
a[14] b[44] c[26].
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towards 3-hydroxy-Δ5 steroids, we performed in vitro
reactions with dehydroepiandrosterone, pregnenolone,
cis-androsterone, trans-androsterone, cholesterol, and
stigmasterine. Estrone, estradiol, as well as prednisone and
dexamethasone were tested as examples for aromatic and
ring-reduced steroids. Additionally, we chose digitoxi-
genin, the steroidal aglycone of the cardio-active glycoside
as a potential substrate with D-ring modification. TLC
and HPLC analysis were performed and steroid conver-
sion has been observed for five out of eleven substances
tested (Table 1). Reaction products were detected using
dehydroepiandrosterone (DHEA), pregnenolone (PREG),
dexamethasone, prednisone, and digitoxigenin as sub-
strates (Scheme 1). According to these results, it can be
stated that the 3-oxo-Δ4 moiety is not crucial for steroid
conversion with CYP106A2. However, estrone, estradiol,
stigmasterol, and cholesterol were not hydroxylated by
CYP106A2. We assume that the lower flexibility of the
aromatic A-ring of the three steroids hinders binding and
hydroxylation. Why cholesterol and stigmasterol are notconverted by CYP106A2 cannot be explained at this point.
The size of these steroids should not be the problem be-
cause CYP106A2 is able to hydroxylate cholestenone and
dipterocarpol which are of similar size. Considering that
cholestenone is the 3-oxo-Δ4 counterpart of cholesterol, it
can be assumed that the 3-oxo-Δ4 motif present in this
case plays a crucial role [26]. Table 1 contains an overview
about all steroids which were tested as substrates for
CYP106A2.
NMR spectroscopy was applied to resolve the structure
of the newly identified CYP106A2 reaction products.
To obtain the required amounts (mg), B. megaterium
ATCC13368 was used for preparative scale whole-cell
conversions. To investigate whether the B. megaterium
ATCC13368 whole-cells are capable to hydroxylate DHEA,
PREG, dexamethasone, prednisone and digitoxin, 500 μl
aliquots of fresh over-night cultures were used for small
scale conversions. For this purpose, 200 μM of each sub-
strate was added to one 500 μl aliquot and incubated for
60 minutes at 30°C under vigorous shaking. TLC and
HPLC analysis revealed that CYP1062-dependent product
formation was only detected with PREG and DHEA as
substrate (Figure 1). Dexamethasone was not converted
in noteworthy amounts by B. megaterium ATCC13368
(Additional file 1: Figure S1). Digitoxigenin and prednisone
were converted in the whole-cell system, but in their case
product formation was also observed using the CYP106A2-
deficient knockout strain (Additional file 1: Figures S2
and S3). Because no evident CYP106A2-dependent con-
version was detected for dexamethasone, prednisone and
digitoxigenin, these substrates were not investigated in
more detail in this work. The interference of other
B. megaterium enzymes or low permeability of the cell
membrane for these substrates are possible reasons why
their whole-cell conversions were not as promising as
those of DHEA and PREG. To circumvent interference
with B. megaterium enzymes, efficient E. coli based whole-
cell systems are an alternative in this case [23,27].
In contrast to the ring-reduced steroids, DHEA and
PREG were converted by B. megaterium ATCC13368 in
sufficient amounts to conduct NMR-analysis. According to
the TLC analysis, the DHEA conversion resulted in the for-
mation of two products (Figure 1). The main reaction
product (Rf 0.43) was identified with NMR-spectroscopy as
7β–OH-DHEA and the minor reaction product (Rf 0.24)
as the 7α stereoisomer (Scheme 2). Whole-cell conversion
of PREG with B. megaterium ATCC13368 resulted also in
the formation of two reaction products (Rf 0.42 and 0.23)
(Figure 1). However, in this case only the main product
(Rf 0.4) was obtained in sufficient amount and purity for
NMR-analysis and was identified as 7β–OH-PREG. Nei-
ther DHEA nor PREG reacted with the cyp106a2-knock-
out strain, why we presume the reaction being strictly
CYP106A2 dependent in B. megaterium whole-cells
Scheme 1 Structures of novel CYP106A2 substrates: digitoxigenin (1), prednisone (2), dexamethasone (3), pregnenolone (4),
dehydroepiandrosterone (5).
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choose DHEA for further investigations.
CYP106A2-dependent in vitro hydroxylation of DHEA
The binding of DHEA to CYP106A2 was analyzed in vitro
using difference spectroscopy. DHEA did not cause any
spectral shift in our assay prompting the assumption that
the steroid is not able to remove the axial water from
the heme during binding (Figure 2a). Interestingly, the
3-oxo-Δ4 counterpart of DHEA, androstenedione, induced
a high-spin shift in our assay (Figure 2b) and could be used
to determine the dissociation constant of androstenedioneFigure 1 In vivo conversion of dehydroepiandrosterone and
pregnenolone with B. megaterium ATCC13368 and B. megaterium
ATCC13368 Δcyp106a2 whole cells. Conversions were performed
using 500 μl samples of fresh 16 h cultures incubated with 200 μM of
the respective steroid for 60 min at 30°C and vigorous shaking in
1.5 ml reaction tubes. Reaction was quenched and extracted with
500 μl ethyl acetate. DHEA was hydroxylated into 7β-OH-DHEA and
7α-OH-DHEA (a), and PREG was converted into 7β-OH-PREG and an
unknown product P2 (b). The cyp106A2-knockout strain converted
neither DHEA nor PREG (a,b).with CYP106A2 to be 92 ± 11 μM (Figure 2c). It is likely
that the keto-group at position 3 in the A-ring leads to an
alternate binding mode of androstenedione, resulting in a
position maybe closer to the heme compared to that of
DHEA, eventually leading to the displacement of the axial
water ligand.
In a next step, the apparent Michaelis-Menten para-
meters describing the CYP106A2 dependent DHEA
hydroxylation have been estimated. The minor product,
7α–OH-DHEA, was produced with an apparent reaction
velocity Vmax
app of 41 ± 3.5 nmol product min−1 * nmol
P450−1 and an apparent Michaelis constant KM
app of 98 ±
22 μM. The reaction leading to the β-hydroxylated pro-
duct is described by a KM
app of 168 μM with an apparent
maximal reaction velocity Vmax
app of 71 nmol product
min−1 * nmol P450−1. In comparison, the 15β-hydroxy-
lation of progesterone is approximately five times faster
with a Vmax
app of 337 nmol product min−1 nmol P450−1. The
conversions of 11-deoxycorticosterone and 11-deoxy-
cortisol are within the same order of magnitude as the
15β-hydroxylation of progesterone with a Vmax
app of
246 nmol product min−1 nmol P450−1 [28], and 172 nmol
product min−1 nmol P450−1 [29]. Bleif et al. showed that
the conversion of triterpene acids like the abietic acid and
the 11-keto-β-boswellic acid is slower than that of the
3-oxo-Δ4-steroids, with Vmax
app values of 22 and 97 nmol
product min−1 nmol P450−1, respectively [17,18]. Thus,
the velocity of the CYP106A2-dependent hydroxylation of
DHEA is comparable to the hydroxylation of terpene acids
with this enzyme.
CYP106A2-dependent in vivo hydroxylation of DHEA
Evaluation of DHEA whole-cell conversion
As mentioned above, cytochrome P450 in vitro reactions
are not suitable for preparative scale production of
hydroxysteroids [8]. Therefore, our aim was to establish
β α
β
Scheme 2 Reaction of dehydroepiandrosterone and pregnenolone with CYP106A2.
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of 7β-OH-DHEA. We used B. megaterium ATCC13368,
which expresses CYP106A2 in the stationary phase of
growth and has been successfully used for preparative-
scale production of CYP106A2 reaction products in the
past, with higher susceptibility for terpenoic substrates
than E.coli [18,19]. As described above, the B. megaterium
strain ATCC13368 approved to be suitable for in vivo
mg scale 7β-hydroxylation of DHEA. To evaluate the
efficiency of DHEA hydroxylation, time-dependent and
substrate concentration-dependent bioconversions were
performed. Steroids are lipophilic compounds and hence
scarcely soluble in water. In order to increase the solubility
of DHEA, ethanol was used as co-solvent. However,
ethanol is toxic to bacterial cells why its use as solvent is
limited in whole-cell biotransformations. It was found that
the growth and viability of B. megaterium was not in-
fluenced by ethanol concentrations up to 5% (data not
shown). Using 5% ethanol as co-solvent, the solubility of
DHEA was increased to 400 μM. Finally, DHEA concen-
trations ranging from 50 to 400 μM DHEA were added to
50 ml cultures and the reaction was followed until the
substrate was consumed (Figure 3). Complete substrate
consumption was observed for all tested concentrations.
50, 75 and 100 μM DHEA were consumed within one
hour (Figure 3). The highest concentration tested,
400 μM, was completely consumed within three hours.
Using 400 μM, fluctuations in the DHEA conversion be-
tween the first three measurement points occurred, which
are most probably caused by incomplete mixing of the
substrate in the culture and an unbalanced uptake of
DHEA into the cells. In order to affirm our finding
that 400 μM DHEA are consumed completely within
180 minutes the conversion using this concentration was
repeated additional three times, in all cases no substrate
was detected anymore after 180 minutes, and more than99% of the substrate was consumed within 120 minutes
(Figure 4.).
Discontinuous DHEA-feed
Using ethanol as co-solvent we were able to dissolve
400 μM DHEA in B. megaterium ATCC13368 cultures.
Using higher DHEA concentrations than 400 μM, how-
ever, aggregation of the substrate was observed. Whereas,
solid substrate does not necessarily circumvent product
formation, substrate aggregation lowers the conversion
rate. To avoid substrate aggregation in the media, a
discontinuous feed of DHEA into the reaction was investi-
gated. Because 400 μM DHEA are completely converted by
B. megaterium ATCC13368 within 180 minutes (Figures 3
and 4), DHEA was fed in 400 μM portions to the cells
with three hours break between the individual additions.
DHEA concentrations in the cultures were measured
before and immediately after the substrate additions. The
first two feeds after 3 and 6 hours resulted in com-
plete DHEA consumption, meaning a total conversion of
800 μM DHEA within 6 hours. After the third feeding
step, complete conversion was detected in two of three
flasks, resulting in a mean conversion of 98 ± 2%. The
conversion rate dropped further after the addition, within
the next 3 hours only 82 ± 14% DHEA were hydroxylated.
The last 400 μM DHEA were not converted into hydro-
xylated products within the following 12 hours (Figure 5).
Altogether, B. megaterium ATCC13368 was able to hy-
droxylate approximately 1.5 mM DHEA within 12 hours,
resulting in a conversion rate of 438.4 mg*l−1 (Figure 5).
Although substrate accumulation was avoided, we en-
countered limitations of the B. megaterium ATCC13368
bioconversion. It can be assumed that the decrease in
activity is caused either by direct inhibition of CYP106A2
or indirectly through negative effects of the accumulating
products on the B. megaterium ATCC13368 metabolism.
Figure 2 Difference spectroscopy measurements of DHEA and
androstenedione binding to CYP106A2. a) Difference spectra of
DHEA with CYP106A2 in tandem cuvettes recorded from 350 to
500 nm. 0, 75, and 100 μM DHEA solved in DMSO were used.
b) Difference spectra of androstenedione recorded from 350 to 500 nm
in tandem cuvettes. Androstenedione was titrated from 0 to 600 μM into
a 10 μM CYP106A2 solution. c) The binding constant KD was calculated
by plotting the peak-to-through difference and subsequent hyperbolic fit
(solid line). The apparent dissociation constant of androstenedione was
calculated to be KD 92 ± 11 μM. The results represent mean values and
standard deviations from three independent titrations.
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B. megaterium ATCC13368 cultures was assessed over a
time-period of 48 hours. For this purpose, cells were
cultivated in broth at 30°C and 500 μl aliquots weresampled after 16, 24, 36, and 48 hours. Conversions were
performed with 100 μM substrate using 500 μl aliquots
in 1.5 ml reaction tubes at 30°C for 30 minutes. The
activity of the cells which were incubated 16 hours prior
to the activity assay was defined as 100% and the activity
of the aliquots taken after 24, 36 and 48 hours was
calculated relative to this value. No decrease in the hy-
droxylation efficiency of B. megaterium ATCC13368 was
observed within 36 hours (Table 2). On the contrary, the
mean conversion, relative to the activity measured after
16 hours, increased to 136%, although it has to be taken
into account that the standard deviation was quite high.
Nevertheless, it can be concluded, that the hydroxylation
efficiency of B. megaterium ATCC13368 is constant
within 36 hours and did not decrease in our experiments
until 48 hours. We therefore assume that the limitation
observed in the discontinuous feeding reaction is caused
by the accumulation of hydroxysteroid in the medium.
However, with 438.4 mg*l−1 DHEA converted within
12 hours (e.g. 36 mg*l−1*h−1) the volumetric productivity
of the systems achieves the minimum process require-
ments for the industrial production of pharmaceuticals,
which is estimated to 1 mg*l−1*h−1 [30].
Whole-cell conversion using resting cells of Bacillus
megaterium
Although an efficient conversion rate was achieved with
438 mg l−1 by stepwise addition of DHEA to the cultures,
the use of whole cells in complex medium hampered the
analysis and subsequent chromatography of the reaction
products, because of huge amounts of media constituents
and B. megaterium metabolites. Resting cells were used to
overcome this problem. An additional advantage of resting
cells is the avoidance of metabolites which accumulate
during bacterial growth and might inhibit the enzyme re-
action. E. coli for instance produces indole by metabo-
lizing tryptophan as carbon source if sugar is depleted and
this indole in turn can act as cytochrome P450 inhibitor
in whole-cell bioconversions [27,31]. However, resting
cells are not always better suited for bioconversions than
growing cells. For the bioconversion of DHEA with B.
megaterium resting cells, 50 ml cultures were incubated
16 hours at 30°C and 150 rpm in complex medium. After-
wards, cells were centrifuged, washed once and suspended
in 50 ml potassium phosphate buffer (50 mM pH adjusted
to 7.4). 400 μM DHEA were added to the reaction mixture
and the conversion was followed using rpHPLC analysis.
As shown in Figure 6, using resting cells, 400 μM DHEA
were completely converted within 60 minutes, whereas it
took 180 minutes to completely convert the same amount
using growing cells (Figures 3 and 4). Taken together, our
experiments demonstrate that the conversion rate was
considerably increased using B. megaterium resting cells
compared with growing cells.
Figure 3 Time- and concentration- dependent DHEA conversions using B. megaterium ATCC13368 whole-cell bioconversion. 50 ml B.
megaterium WT cultures were incubated at 30°C and 150 rpm for 16 hours prior to substrate addition. 50, 75, 100 and 400 μM DHEA (max. 5%
ethanol v/v) were added into the cultures and reactions were followed using TLC analysis. Samples were taken at indicated time points, (500 μl)
quenched, and extracted with 500 μl ethyl acetate. The organic phase was separated, evaporated to dryness, and chromatographed using ethyl
acetate as mobile phase on TLC-plates. After anisaldehyde staining the relative substrate consumption in % was calculated using the spot intensity
with the Image-Lab™ (BIO-RAD, Germany) software.
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MS941_pSMF2.1CAA strain
B. megaterium ATCC13368 expresses CYP106A2 in the
stationary phase of growth. The maximum P450 content
in our experiments was reached after 24 hours withFigure 4 Conversion of 400 μM DHEA. 50 ml B. megaterium
ATCC13368 cultures were incubated 16 hours at 30°C and 150 rpm.
DHEA (400 μM dissolved in ethanol) was added and cultures were
incubated additional 180 min. 500 μl samples were taken at 0, 15, 30,
45, 60, 120 and 180 minutes after substrate addition. Samples were
quenched and extracted with 500 μl ethyl acetate, evaporated to
dryness and chromatographed using ethyl acetate as mobile phase.
After anisaldehyde staining the relative substrate consumption in %
was calculated using the spot intensity with the Image-Lab™ (BIO-RAD,
Germany) software. The graph shows the mean values and standard
deviation from three independent conversions.135 nmol*l−1 culture (Figure 6). No P450 was detected in
the respective knock-out strain (Figure 6). For biotech-
nological purposes, it would be of interest to increase the
expression rate of CYP106A2 and its redox partners.
However, no inducer of CYP106A2 expression in B. mega-
terium is known so far. In our experiments, DHEA was
also not able to induce CYP106A2 expression in B. mega-
terium. In order to increase the CYP106A2 amount in
B. megaterium, an expression system for CYP106A2
together with its heterologous redox partners AdR and
Adx4-108 in the strain B. megaterium MS941 has been
developed in our laboratory [18]. Using this system, the
expression rate of P450 averages 450 nmol*l−1 culture, dis-
playing a three-fold increase compared to the wild type
strain (Figure 7). Although B. megaterium MS941 contains
four P450s in its genome [32], Western Blot analysis con-
ducted by Bleif et al. showed that the P450 content in the
expression system is mainly composed of CYP106A2.
Using this overexpression strain, the conversion rate of
11-keto-β-boswellic acid was increased by the factor of
four compared with the wild type [18]. Therefore, we
aimed to improve the DHEA conversion using the recom-
binant expression strain B. megaterium MS941 overex-
pressing CYP106A2. According to the results achieved
with the ATCC13368 strain (shown in Figure 6), resting
cells were used for the bioconversion. Again, 400 μM
DHEA was added and samples were taken after 0, 1, 4, 8
and 24 hours. To corroborate the CYP106A2 dependence
of DHEA conversion, the MS941 strain without the ex-
pression vector was used as control. The control strain did
not convert DHEA within 24 h of incubation (Additional
Figure 5 Discontinuous feed of DHEA to B. megaterium
ATCC13368. B. megaterium ATCC13368 cultures were incubated at
30°C and 150 rpm in broth. After 16 h cultivation 400 μM DHEA was
added (0 h) 5 times with 3 hours break between the individual
additions. After the last addition (reaching 2000 μM DHEA in total)
the cultures were incubated for additional 12 h. DHEA concentration
in the cultures was calculated using TLC analysis and the software
ImageLab™ (BIO-RAD, Germany).
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B. megaterium MS941_pSMF2.1CAA cells was compar-
able to that of resting cells of the ATCC13368 strain,
400 μM DHEA were completely converted after 60 mi-
nutes (Figure 6). Obviously, there are other rate-limiting
parameters in CYP106A2-dependent DHEA conversion in
B. megaterium, most probably substrate uptake and pro-
duct exit, which are known bottlenecks of whole-cell con-
versions. Interestingly, the product pattern differed in the
reactions performed with the ATCC13368 strain from that
using the recombinant expression system. The latter
shifted the selectivity in favor of the reaction leading to the
β-hydroxylated product. The ATCC13368 strain converted
DHEA into 70% 7β-OH-DHEA and 30% 7α-OH-DHEA,
whereas the MS941_pSMF2.1CAA strain produced 90%
7β-OH-DHEA (Figure 6, Additional file 1: Figure S4).
Although no increase in the conversion rate could be mea-
sured with the overexpression strain, due to the increased
stereoselectivity a time-space yield 103 mg*l−1*h−1 7β-OH-
DHEA was calculated using this system, reflecting theTable 2 Hydroxylation activity of B. megaterium
ATCC13368 monitored over a period of 48 hours
16 h 24 h 36 h 48 h
100% 105 ± 3% 136 ± 42% 84 ± 22%
Cells were cultivated in 50 ml Erlenmeyer flasks at 30°C and 150 rpm. 500 μl
samples were taken at time points indicated. Conversions were performed
with 100 μM substrate in 1.5 ml reaction tubes at 30°C for 60 min. The
reactions were quenched and extracted with ethyl acetate and the steroid
conversion was analyzed with HPLC. The activity of B. megaterium after 16 h
cultivation was defined as 100%. Results are shown as mean values and
deviations are from two independent experiments.fastest CYP106A2-dependent hydroxysteroid production
described using B. megaterium whole-cells up to now.
At this point it cannot be fully explained why the use
of the recombinant expression system alters the selec-
tivity of the reaction. However, similar observations have
been made with the E. coli system for the production of
hydroxylated progesterone derivatives using CYP106A2
mutants, were the in vitro selectivity differed from that
observed in the in vivo conversions [33].
Conclusions
Summarizing the results, we broadened the substrate
spectrum of CYP106A2 and identified novel reaction pro-
ducts. Screening of a focused steroid library revealed, for
the first time, that CYP106A2 converts 3-hydroxy-Δ5 and
A-ring reduced steroids. The major group of CYP106A2
substrates still consists of 3-oxo-Δ4 steroids, but the pre-
sent work describes for the first time its ability to hydro-
xylate pregnenolone (PREG) and dehydroepiandrosterone
(DHEA), both mainly at position 7β. Assuming that both
ends of the steroid molecule interact with amino acid side
chains to position the steroid above the heme, four princi-
pal binding modes have been described in the literature;
normal, reverse, normal inverted and reverse inverted [34].
The differences in the hydroxylation position of 3-oxo or
3-hydroxy steroids most probably result from alternative
binding modes in the active side of CYP106A2, assessing,
for instance, the differences between DHEA and andro-
stenedione hydroxylation: The change of the hydrogen-
bond-acceptor (=O) into a donor (−OH), at position C-3,
may cause an inverted or reversed binding of the molecule.
Another possible explanation is that the loss of one hydro-
gen-bond acceptor loosens the binding at C-3, so that the
steroid slips perhaps deeper into the reactive pocked resul-
ting in that the C-15 is moved from and the C-7 towards
the heme-iron.
Even though the mechanistic insights of CYP106A2
steroid hydroxylation remain elusive, its production of
human DHEA metabolites is highly interesting, because
7-oxygenated DHEA derivatives have been discussed as
neuroprotective, immune-modulatory and anti-inflamma-
tory agents [35]. Besides, hydroxylated steroids are highly
interesting lead compounds for drug development targeting
P450 enzymes, especially CYP19A1 (aromatase) which is
involved in the formation of post-menopausal breast
cancer. Li et al., for instance, showed that 7-substituted
1,4,6-androstatriene-3,17-diones can act as enzyme-acti-
vated irreversible aromatase inhibitors [36]. The biocon-
version rates of the systems described achieve appreciable
rates, up to 400 μM DHEA within one hour, thus compar-
able to described fungal systems [37]. To our opinion the
major challenge for further optimizations of DHEA biocon-
version with B. megaterium is the limitation most probably
caused by accumulation of hydroxysteroids in the reaction
Figure 6 HPLC chromatograms of DHEA conversion using resting cells B. megaterium ATCC13368 (wt) and MS941_pSMF2.1CAA (CAA).
Cultures were incubated at 30°C and 150 rpm for 24 h, washed once and suspended in 50 ml potassium phosphate buffer adjusted to pH 7.4.
Heterologous protein expression in B. megaterium MS941_pSMF2.1CAA cells was induced with 0.5% (w/v) xylose. DHEA (400 mM) was added as
ethanolic solution (5% v/v). Samples were taken directly after substrate addition (CAA 0 h, wt 0 h) and after 1 h (CAA 1 h, wt 1 h). No DHEA
(RT = 11.5 min) was detected in the 1 h samples.
Figure 7 P450 content in the used B. megaterium strains.
CO-difference spectra recorded after 24 hours cultivation of B. megaterium
ATCC13368 (wt), cyp106a2-knockout strain (k.o. strain), and MS941_pSMF2.
1CAA (CAA) in crude lysates. Cells were incubated at 30°C and 150 rpm
in broth, which was supplemented with 35 μg/ml tetracycline for
the cultivation of B. megaterium ATCC13368 cyp106a2-knockout and B.
megaterium MS941 cells. The protein expression in MS941_pSMF2.1CAA
cells was induced by adding 0.25% xylose to the culture at OD600 of 0.4
and subsequent incubation for 24 hours.
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liquid-liquid biphasic-systems, in which a water-immiscible
liquid phase is used as substrate reservoir and product
recipient. Such systems have already been successfully
conducted with recombinant E. coli and solvent tolerant
Pseudomonas putida strains [38,39]. Yet, combined with
the recombinant expression strain, which produced the
7β-stereoisomer with 90% de resulting in a space-time
yield of 103 mg*l−1*h−1 7β-OH-DHEA, the present sys-
tems provides an excellent starting point to establish bio-




All chemicals used in this work were from standard
sources and of highest purity available. Solvents used for
chromatography were of gradient grade, solvents used
for large scale extraction were of analytical purity. The
focused steroid library used in this work consisted of:
dehydroepiandrosterone (DHEA), pregnenolone (PREG),
estradiol, estrone, dexamethasone, prednisone, androstene-
dione, stigmasterol, cholesterol and cis-, trans-androster-
one. All steroids were obtained from Sigma-Aldrich
(Sigma-Aldrich Biochemie GmbH, Germany) and were of
highest purity available.
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Bacillus megaterium ATCC13368, the host strain of
CYP106A2, as well as a respective knockout strain Bacillus
megaterium ATCC13368 Δcyp106A2, were both kind gifts
of Dr. R. Rauschenbach (Schering AG, Berlin, Germany).
Bacillus megaterium MS941 was kindly provided by Prof.
Dieter Jahn (Institute of Microbiology, TU Braunschweig,
Germany). Besides, we used a xylose-inducible recom-
binant expression system, which has recently been esta-
blished in our group, to co-express CYP106A2 and its
heterologous redox-partners adrenoxodin (Adx) and adre-
nodoxin reductase (AdR) using the expression vector
pSMF2.1_CAA in B. megaterium MS941 [18].
Unless otherwise noted, Bacillus megaterium cells
were cultivated in complex medium consisting of 25 g
yeast extract (Becton, Dickinson and Company, USA),
12 g soytone (Becton, Dickinson and Company, USA)
and 5 ml glycerol buffered with potassium phosphate
buffer (2.31 g KH2PO4, 12.5 g K2HPO4) adjusted to
pH 7.4 in 1 l distilled water. Cultivations were generally
conducted at 30°C and 150 rpm in baffled shake-flasks
(300 ml or 2 l). For the cultivation of MS941 cells
transformed with the plasmid pSMF2.1_CAA and for
the cultivation of the ATCC13368 Δcyp106a2-strain the
medium was supplemented with 10 mg*l−1 tetracycline.Protein expression and purification
CYP106A2, a truncated form of bovine adrenodoxin
(Adx4-108) and bovine adrenodoxin reductase (AdR)
were expressed and purified as described elsewhere
[19,40,41].In vitro conversion and catalytic activity
Substrate conversions with CYP106A2 were conducted
using an in vitro reconstituted system with bovine Adx4-108
(5 μM) and bovine AdR (0.5 μM) as redox partners for
CYP106A2 (0.25 μM). An NADPH regeneration system
consisting of glucose-6-phosphate-dehydrogenase (1 U),
glucose-6-phosphate (5 mM) and MgCl2 (1 mM) was used
for the continuous supply with electrons. Reactions were
carried out in 1.5 ml reaction tubes at 30°C and 750 rpm
in 50 mM HEPES-buffer adjusted to pH 7.4 and sup-
plemented with 0.05% (v/v) Tween 20. The total reaction
volume was 250 μl. Reactions were started by adding
500 μM pre-warmed (30°C) NADPH dissolved in 50 mM
HEPES-buffer. For the endpoint-kinetics the reactions
were incubated for two minutes. The reaction times were
ten minutes in order to screen the steroid library for
novel CYP106A2 substrates. Reactions were stopped and
extracted twice with 500 μl ethyl acetate. The organic
phases were pooled, evaporated to dryness and subse-
quently chromatographed via reversed-phase high-per-
formance-liquid-chromatography (rpHPLC).Spectroscopic binding assay
Difference spectroscopy was used to investigate the binding
behavior of DHEA and androstenedione to CYP106A2.
For this purpose, tandem cuvettes were used as described
in the literature [42,43]. In one chamber of each cuvette
10 μM enzyme in 50 mM potassium phosphate buffer
(pH 7.4) was added, whereas buffer without enzyme was
filled into the other chamber. After performing the base-
line correction, steroids were titrated into the enzyme so-
lution of the measurement cuvette and into the chamber
containing only buffer of the reference cuvette. The sol-
vent DMSO alone was titrated vice versa to avoid falsifica-
tion of the measurement according to imbalanced dilution
of the enzyme solution. After baseline correction, the dif-
ference spectra were recorded from 300 to 500 nm. For
the steroids 5 mM, 10 mM and 40 mM stock solutions
were prepared using DMSO as solvent. Titrations were
performed using a maximal concentration of 2% DMSO
(v/v) and final steroid concentrations ranging from
0 – 600 μM. The KD value was calculated by plotting the
peak-to-through differences ΔA (380 nm – 417 nm)
against the total ligand concentration. The apparent equi-
librium dissociation constant was calculated by hyperbolic
regression of the resulting plot (y = (P1x/P2 + x) with
P2 = KD) using the origin software version 8.6 (OriginLab
Corporation, Massachusetts, USA).
Whole-cell biotransformations
Whole cell bioconversions were performed with B. mega-
terium ATCC 13368 and B. megaterium MS941_pSMF2.
1CAA cultures. As control a Δcyp106a2 knock-out strain
of B. megaterium ATCC 13368 [44] and the MS941 strain
without the expression plasmid for CYP106A2 were used.
In each case pre-cultures were prepared by inoculating
50 ml broth (25 g yeast extract, 12 g soytone, 5 ml gly-
cerine and no further additives) with 50 μl of deep-frozen
stocks and incubated 24 hours at 30°C and 150 rpm in
baffled flasks. Main cultures were inoculated by diluting
an aliquot of the pre-cultures 1 to 100 with fresh medium.
For the incubation of B. megaterium ATCC 13368 cells
the cultures were incubated 16 h depicting the stationary
phase of growth, to ensure the expression of CYP106A2.
To express CYP106A2 with B. megaterium MS941 strain
transformed with the expression plasmid pSMF2.1_CAA,
0.25% (w/v) xylose were added for induction when the
main culture reached OD600 of 0.4. Protein expression
was conducted for 24 hours after induction as described
[18]. The 16 h cultures of the ATCC13368 and the 24 h
cultures of the MS941_pSMF2.1CAA strain, consistent
with an OD of 20 and approximately 40 g-wcw per liter
were used for whole-cell conversions. Substrates were ge-
nerally added as ethanolic solutions, with the final ethanol
concentration not exceeding 5% (v/v). Unless otherwise
stated, conversions were performed with 50 ml cultures in
Schmitz et al. Microbial Cell Factories 2014, 13:81 Page 11 of 13
http://www.microbialcellfactories.com/content/13/1/81300 ml baffled shake flasks at 30°C and 150 rpm using the
soytone containing broth or 50 mM potassium phosphate
buffer (resting cell conversions). Samples were taken at
indicated time points; reactions were quenched and con-
comitantly extracted with 500 μl ethyl acetate. To follow
the CYP106A2 catalyzed reactions, the organic phases
were collected, evaporated to dryness, and analyzed via
HPLC or TLC.
For the preparative scale conversions of dehydroepian-
drosterone (DHEA) and pregnenolone (PREG), 1 L cul-
tures, distributed to five 2 L baffled shake flasks (200 ml
each), were inoculated with 1 ml of a deep-frozen stock
(200 μl each) and cultivated for 16 h at 30°C and 150 rpm.
115 mg of DHEA and 120 mg of PREG, respectively, were
dissolved in 50 ml ethanol and added to the cultures after
16 h incubation. Samples were taken every two hours and
reactions were monitored using TLC analysis. When the
substrate was completely consumed, the cultures were
pooled and extracted three times with 500 ml ethyl acet-
ate. The organic phases were combined, dried and the
resulting residue was chromatographed via a silica gel (60)
column, using ethyl acetate as mobile phase. 10 ml frac-
tions were collected and analyzed via TLC; homogenous
fractions containing the reaction products were pooled
and evaporated to dryness. Because of a yellowish im-
purity, the main product of the DHEA reaction was ad-
ditionally chromatographed via a silica gel column using a
mixture of hexane/ethyl acetate/methanol in a ratio of
1:4:0.5 as mobile phase. The resulting homogeneous
fractions were evaporated to dryness and analyzed by
TLC. Those products which were obtained in sufficient
amounts and purity were analyzed by NMR spectroscopy.
The yields after silica gel chromatography were 46 mg for
the first DHEA reaction product (chromatographed
twice), 23 mg for the second reaction product and 42 mg
for the main pregnenolone product and approximately
1 mg for the second pregnenolone product.
Chromatographic methods
TLC was used to monitor the in vivo biotransformation
using growing cells in complex medium and for the
analysis of homogenous fractions obtained after silica gel
column chromatography. Samples were spotted onto TLC
aluminum plates (4 x 8 cm; silica 60; layer thickness,
0.2 mm; Roth, Karlsruhe, Germany), and developed once
in a rectangular solvent tank containing ethyl acetate as
mobile phase. Spots were detected using an anisaldehyde
dipping bath (4-methoxybenzaldehyde, 5 ml; sulfuric acid,
2.5 ml; glacial acetic acid, 3.75 ml; ethanol, 278.75 ml), the
reaction of anisaldehyde-sulfur reagent with the steroids
and terpenoids to colored products was started by heating
the plates to 100°C using a hot air gun.
Reversed-phase high-performance-liquid-chromatography
(HPLC) was performed using a Jasco system (Pu-980HPLC pump, an AS-950 sampler, and UV-975 UV/visible
detector, and a LG-980-02 gradient unit from Jasco, Gross-
Umstadt, Germany). A reversed phase ec MN Nucleodor
C18 (5 μm, 4.0 × 125 mm) column (Macherey-Nagel,
Bethlehem, PA, USA) was used. A mixture of acetonitrile
and water (40:60) served as mobile phase. Steroids contain-
ing a keto-en moiety were detected at 254 nm. From the
set of steroids without keto-en-moiety only DHEA was
monitored with rpHPLC at 210 nm, but only after con-
version in vitro or with resting cells, because the samples
from whole-cell conversions in complex-media included to
many impurities, hampering the rpHPLC analysis at
210 nm. In all measurements the column oven tem-
perature was kept at 40°C and the flow rate of the mobile
phase was 1 ml*min−1.
NMR spectroscopy
NMR spectra were recorded in CDCl3 at 300 K with a
Bruker DRX 500 NMR spectrometer. The chemical shifts
were given relative to CDCl3 at δ 77.00 (
13C NMR) or
CHCl3 at δ 7.24 (
1H NMR) using the standard δ notation
in parts per million (ppm). The 2D NMR spectra were
recorded as gs-HHCOSY, gs-NOESY, gs-HSQCED and
gs-HMBC.
The conversion of DHEA led to the production of the
known 7α-OH- and 7β-OH-DHEA epimers. Their struc-
tures followed directly from the comparison of their
NMR data with those from literature [45].
3β,7α-Dihydroxyandrost-5-en-17-one (7α-OH-DHEA)
1H NMR (CDCl3, 500 MHz) : δ 0.86 s (3H, 3x H-18), 0.99 s
(3H, 3x H-19), 1.09m (H-1a), 1.25m (H-12a), 1.26m
(H-9), 1.48m (H-11a), 1.49m (H-2a), 1.55m (H-15a),
1.64m (H-8), 1.68m (H-11b), 1.77m (H-14), 1.80 m
(H-12b), 1.83m (H-2b), 1.85m (H-1b) 2.08 m (H-15b),
2.12m (H-16a), 2.27 m (H-4a), 2.34 m (H-4b), 2.45 m
(H-16b), 3.54 m (H-3), 3.94 dd (J = 5.0 and 5.0 Hz, H-7),
5.61 dd (5.0 and 2.0 Hz, H-6). 13C NMR (CDCl3,
125 MHz): δ 13.29 (C-18), 18.28 (C-19), 20.09 (C-11),
21.93 (C-15), 31.07 (C-12), 31.30 (C-2), 35.80 (C-16),
36.97 (C-1), 37.22 (C-10), 37.53 (C-8), 41.95 (C-4), 42.62
(C-9), 44.96 (C-14), 47.11 (C-13), 64.28 (C-7), 71.17 (C-3),
123.57 (C-6), 146.57 (C-5), 221.10 (C-17).
3β,7β-Dihydroxyandrost-5-en-17-one (7β-OH-DHEA)
1H NMR (CDCl3, 500 MHz): δ 0.88 s (3H, 3x H-18),
1.05m (H-1a), 1.06 s (3H, 3x-H19), 1.08m (H-9), 1.23m
(H-12a), 1.42 m (H-14), 1.48m (H-11a), 1.50m (H-2a),
1.55m (H-8), 1.68m (H-11b), 1.82m (H-12b), 1.83m
(H-15a), 1.84m (H-1b), 1.85m (H-2b), 2.09m (H-16a),
2.22m (H-15b), 2.24m (H-4a), 2.33 ddd (J = 13.5, 5.0
and 2.0 Hz, H-4b), 2.45m (H-16b), 3.53m (H-3), 3.93
ddd (J = 8.0, 2.0 and 2.0 Hz, H-7), 5.29 dd (J =2.0
and 2.0 Hz, H-6). 13C NMR (CDCl3, 125 MHz): δ 13.60
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(C-12), 31.51 (C-2), 35.98 (C-16), 36.69 (C-10), 36.90
(C-1), 40.52 (C-8), 41.67 (C-4), 47.78 (C-13), 48.27 (C-9),
51.23 (C-14), 71.27(C-3), 72.88 (C-7), 125.50 (C-6),
143.75 (C-5), 221.11 (C-17).
In contrast to pregnenolone the NMR spectra of its con-
version product gave hint to an additional hydroxyl group
(δ 73.14 (CH) and δ 3.83). Its position at C-7 was deduced
from HMBC correlations between H-7 and the carbons
C-5 (δ 143.49 (C) and C-6 (δ 125.49 (CH)) of the double
bond and the vicinal coupling of H-7 with H-6 (δ 5.27) in
the HHCOSY. The NOESY spectrum revealed correla-
tions between H-7 and the axial H-9 (δ 1.07) and H-14
(δ 1.27) indicating that all these protons are in axial posi-
tion and logically consistent the hydroxyl group at C-7 is
equatorial and therefore in β-orientation. Therefore its
NMR data were in good accordance to those of the close
related 3β, 7β-dihydroxyandrost-5-en-17-one.
3β, 7β-dihydroxypregn-5-en-20-one (7β-OH-PREG)
1H NMR: (CDCl3, 500 MHz): δ 0.63 s (3H, 3 x H-18),
1.03 s (3H, 3 x H-19), 1.06m (H-1a), 1.07m (H-9), 1.27
m (H-14), 1.39m (H-12b), 1.40m (H-8), 1.47m (H-11a),
1.50m (H-2a), 1.56m (H-15a), 1.62m (H-11b), 1.70m
(H-16a), 1.84m (2H, H-1b and H-2b), 1.92m (H-15b),
2.03m (H-12b), 2.11 s (3H, 3x H-21), 2.18m (H-16b),
2.23m (H-4a), 2.32 ddd (J = 13.5, 5.0 and 2.0 Hz, H-4b),
2.48 dd (J = 9.5 and 9.5 Hz, H-17), 3.53m (H-3), 3.83
ddd (J = 8.0, 2.0 and 2.0 Hz, H-7), 5.27 dd (J = 2.0 and
2.0 Hz, H-6). 13C NMR (CDCl3, 125 MHz): δ 13.20
(C-18), 19.14 (C-19), 21.04 (C-11), 23.35 (C-16), 26.68
(C-15), 31.53 (C-2), 31.59 (C-21), 36.58 (C-10), 36.91
(C-1), 38.64 (C-12), 41.09 (C-8), 41.49 (C-4), 44.42
(C-13), 48.12 (C-9), 56.03 (C-14), 63.05 (C-17), 71.36
(C-3), 73.14 (C-7), 125.49 (C-6), 143.49 (C-5), 209.54
(C-20).
Additional file
Additional file 1: Figure S1. Dexamethasone conversion with B.
megaterium ATCC13368: Dexamethasone (200 μM) was added to 500 μl
sample of a 16 h culture of B. megaterium ATCC13368 wild type and
cyp106a2-knockout and incubated for 60 minutes at 30°C. Figure S2.
Prednisone conversion with B. megaterium ATCC13368: Prednisone
(200 μM) was added to 500 μl sample of a 16 h culture of B. megaterium
ATCC13368 wild type and cyp106a2-knockout and incubated for 60 minutes
at 30°C. Figure S3. Digitoxigenin conversion with B. megaterium
ATCC13368: Digitoxigenin (200 μM) was added to 500 μl sample of a 16 h
culture of B. megaterium ATCC13368 wild type and cyp106a2-knockout and
incubated for 60 minutes at 30°C. Figure S4. Conversion of DHEA with the
B. megaterium MS941 strain without expression plasmid: Conversions were
conducted in 50 mM potassium-phosphate buffer adjusted to pH 7.4, at
30°C and 150 rpm in 300 ml baffled shake flasks. 400 μM DHEA were added
and samples taken at indicated time-points. No remarkable DHEA conversion
was detected after 24 hours. The impurity eluting at about minute 1, is most
probably a metabolite from the B. megaterium MS941 cells, independent
from CYP106A2 dependent DHEA conversion. Figure S5. Selectivity of
DHEA-hydroxylation with the B. megaterium ATCC13368 wild type straincompared with the B. megaterium MS941_pSMF2.1CAA overexpression
strain: Conversions were performed with 24 h cultures of both strains for
60 minutes in 50 mM potassium-phosphate buffer and DHEA. The amount
of the respective products in percent was calculated using the peak
area/min. The bars show the mean values and standard deviations from
three independent conversions.
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